Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 603-520-1 | CAS number: 131807-57-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- two-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-4 (Reproduction and Fertility Effects)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: MAFF Testing Guidelines for Toxicology Studies NohSan59, No. 4200
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Reference substance name:
- 5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione
- EC Number:
- 603-520-1
- Cas Number:
- 131807-57-3
- Molecular formula:
- C22H18N2O4
- IUPAC Name:
- 5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- Substance ID: DPX-JE874-221 Technical
Lot #: DPX-JE874-221
Purity: 97.4%
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD®BR
- Details on species / strain selection:
- The Crl:CD®BR rat has been selected on the bases of extensive experience with this strain and its suitability with respect to longevity, hardiness, sensitivity, and low incidence of spontaneous diseases.
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- acetone
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples (approximately 10 grams each) were collected from each concentration of diet prepared with the test substance on test days -1 and 62 of the P1 generation and days 65 and 121 of the F1 generation.
The measured concentrations of the test substance in the recovery samples that were prepared with each diet analysis were 105.6 to 111.5% of nominal at the low concentrations and 87.2 to 109.9% of nominal at the high concentrations. These data indicate that the method performed satisfactorily over the entire concentration range.
Measured concentrations of the test substance in samples of test day -1, were 19.7 to 19.9 ppm at the 20 ppm level (C.V. = 0.51% for top, middle, and bottom); from 194 to 214 ppm at the 200 ppm level (C.V. = 5.1%); and from 768 to 842 ppm at the 800 ppm level (C.V. = 5.4%). These data indicate that the test substance was distributed homogeneously in the diet. Test substance was not detected in control diet.
Concentrations of the test substance were from 92.4 to 101.1% of nominal for all storage conditions. These data indicated that test substance was stable in diets that were stored at room temperature for 7 or 14 days or refrigerated for 14 days.
Diet samples were prepared on test day 62, P1, test day 65, F1, and test day 121, F1. Measured concentrations of the test substance in these samples were from 97.0 to 107.0% of nominal, 97.5 to 109.9% of nominal, and 102.6 to 110.0% of nominal, respectively. The test substance was not detected in control diets for any of the submittals. - Duration of treatment / exposure:
- For 2 generations (approximately 9 weeks of age (P1) to scheduled necropsy (F1))
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 20 ppm
- Dose / conc.:
- 200 ppm
- Dose / conc.:
- 800 ppm
- No. of animals per sex per dose:
- 30
- Control animals:
- yes, plain diet
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increase in the incidence of diarrhea in P1 males in the rats fed 800 ppm. Statistically significant increase in the incidence of alopecia for P1 females during gestation in the rats fed 800 ppm.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant reductions in mean body weight, and overall mean body weight gain for P1 males in the rats fed 800 ppm. Statistically significant reduction in mean body weight for P1 females during gestation and on lactation days 0, 7, and 14 in the rats fed 800 ppm.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant reductions in overall mean food consumption for P1 males, for P1 males during premating and gestation in the rats fed 800 ppm.
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant reductions in overall mean food efficiency for P1 males during premating in the rats fed 800 ppm.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Evidence for altered lipid metabolism; statistically significant decrease in mean triglyceride concentration for P1 males and females, and statistically significant increase in mean cholesterol concentration for P1 females in the rats fed 800 ppm.
Statistically significant increase in hepatic enzyme activities and serum bilirubin concentration indicating hepatocellular injury and cholestasis for P1 males in the rats fed 800 ppm. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increase in hepatic peroxisomal ß-oxidation rate for P1 males and females in the rats fed 800 ppm.
Reproductive function / performance (P0)
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- There were no biologically or statistically significant dose-related differences in mating, fertility, or gestation indices, implantation efficiency, or gestation length in the P1 generation.
Effect levels (P0)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 200 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- body weight and weight gain
- food consumption and compound intake
- food efficiency
- clinical biochemistry
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increase in the incidence of alopecia for F1 females during the premating and gestation in the rats fed 800 ppm.
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- For F1 litters of 800 ppm females, 0-4 day viability was statistically significantly reduced, however, that reduction was considered not to be adverse since the value (98.8%) fell well within the range of control data.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significantly reduced mean pup weight throughout the 21-day lactation period for F1 litters in the rats fed 800 ppm.
Statistically significant reductions in mean body weight, and overall mean body weight gain for F1 males in the rats fed 800 ppm.
Statistically significant reduction in mean body weight for F1 females on lactation days 0, 7, and 14 in the rats fed 800 ppm. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant reductions in overall mean food, consumption for F1 males during premating and gestation in the rats fed 800 ppm.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Evidence for altered lipid metabolism; statistically significant decrease in mean triglyceride concentration for F1 males and females, and statistically significant increase in mean cholesterol concentration for F1 males and females in the rats fed 800 ppm.
Statistically significant increase in hepatic enzyme activities and serum bilirubin concentration indicating hepatocellular injury and cholestasis for F1 males in the rats fed 800 ppm. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increase in mean relative liver weight for F1 females in the rats fed 800 ppm. Statistically significant decreases in mean absolute liver weight for F1 males in the rats fed 800 ppm.
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increase in hepatic peroxisomal ß-oxidation rate for F1 males and females in the rats fed 800 ppm.
Details on results (F1)
Effect levels (F1)
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 200 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
Results: F2 generation
General toxicity (F2)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significantly reduced mean pup weight from postpartum day 4 through the end of lactation period for F2 litters in the rats fed 800 ppm.
Effect levels (F2)
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F2
- Effect level:
- 200 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Rat NOAEL (Parental and offspring): 200 ppm
- Executive summary:
A two-generation reproduction study was conducted with the test substance involving the production of one set of litters in each generation according to the guidelines OECD 416 and EPA 83-4. Throughout this study, rats (30/sex/concentration) were fed diets containing concentrations of 0, 20, 200, or 800 ppm. Following at least 70 days of diet administration, the animals were bred within their respective treatment groups, and allowed to deliver and rear their offspring until weaning (postpartum day 21). At weaning, 30 F1 rats/sex/group were randomly selected to produce the next generation. At least 105 days after weaning, the F1 rats were bred within their respective treatment groups to produce F2 litters. Barring F1 weanlings selected for propagation of the next generation, twenty F1 and F2 weanlings/ sex/concentration were designated for gross postmortem examination. The remaining unselected weanlings were sacrificed without pathological examination.
Prior to mating, clinical chemistry evaluations were performed on selected adult animals (10/sex/concentration) in both generations. After litter production, all parental rats were given a gross pathological examination. Testes (weighed), epididymides, prostate, seminal vesicles, coagulating gland, and pituitary were collected from each male. Ovaries, uterus, cervix, vagina, and pituitary were collected from each female. Livers of all adult animals were weighed and peroxisomal ß-oxidation assays were performed on liver samples of selected adult animals (5/sex/concentration) in both generations that had undergone clinical chemistry evaluations. The loss of liver samples resulted in ß-oxidation-evaluation of only 4 rats/group in the 200 ppm P1 male and F1 male and female groups. Tissues from rats in the control and 800 ppm groups of both generations were examined microscopically. In addition, gross lesions and target organs from adult rats in all dose groups were microscopically examined.
At the 800 ppm level, adverse effects considered to be related to the treatment include:
- Statistically significant reductions in mean body weight, and overall mean body weight gain for P1 and F1 males.
- Statistically significant reductions in overall mean food, consumption for P1 and F1 males, and overall mean food efficiency for P1 males during premating.
- Statistically significant increase in the incidence of diarrhea in P1 males.
- Statistically significant reductions in mean body weight, overall mean body weight gain, and overall mean food consumption for P1 and F1 females, and overall mean food efficiency for P1 females during the premating period.
- Statistically significant reductions in mean body weight and overall mean food consumption for P1 and F1 females during gestation.
- Statistically significant reduction in mean body weight for P1 and F1 females on lactation days 0, 7, and 14.
- Statistically significant increase in the incidence of alopecia for F1 females during the premating period and for P1 and F1 females during gestation.
- Statistically significantly reduced mean pup weight throughout the 21-day lactation period for F1 litters and from postpartum day 4 through the end of lactation period for F2 litters.
- Statistically significant increase in hepatic peroxisomal ß-oxidation rate for P1 and F1 males and females.
- Statistically significant increase in mean relative liver weight for P1 and F1 females.
- Evidence for altered lipid metabolism; statistically significant decrease in mean triglyceride concentration for P1 and F1 males and females, and statistically significant increase in mean cholesterol concentration for P1 and F1 females and F1 males.
- Statistically significant decreases in mean absolute liver weight for P1 and F1 males, and mean relative liver weight for P1 males.
- Statistically significant increase in hepatic enzyme activities and serum bilirubin concentration indicating hepatocellular injury and cholestasis for P1 and F1 males.
No adverse compound-related effects were observed at dose levels of 200 ppm and below. Therefore, the no-observed-effect level (NOEL) for adult rats and their offspring was 200 ppm.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.